EDMONTON, AB, November 15, 2021 -- Entos Pharmaceuticals and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline.

  • Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases
  • BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for genetic diseases
  • Entos’ most advanced clinical program is Covigenix VAX-001, a COVID-19 DNA vaccine that is the subject of an ongoing phase 2 clinical trial in South Africa.
  • Licensees of the Fusogenix platform include Oisín Biotechnologies and OncoSenX, for age-related diseases and oncology applications, respectively.


“As a company committed to addressing the unmet therapeutic needs of patients living with genetic diseases, BioMarin values novel technologies that enable the development of transformative therapies,” said Brinda Balakrishnan, M.D., Ph.D., Group Vice President, Corporate and Business Development at BioMarin. “We believe that Entos’ Fusogenix platform offers potentially unique benefits for safe and effective tissue targeting compared with other lipid-based delivery systems. The Fusogenix PLV formulations generated under this agreement are a critical first step in determining how we may incorporate this promising platform into our drug development efforts.”


“With a 20-year track record of successfully discovering, developing, and commercializing first- or best-in-class therapies for diverse rare diseases, the BioMarin team has extensive expertise in harnessing the potential of breakthrough technologies,” said John Lewis, Ph.D., Founder and Chief Executive Officer of Entos. “We believe this agreement helps validate the potential of our Fusogenix platform. It also provides additional opportunities for incorporating our technology into cutting-edge treatments that may have significant clinical and commercial value.”


Under the terms of the agreement, Entos will use its Fusogenix nucleic acid delivery system to specially formulate BioMarin products directed at multiple undisclosed genetic disease indications. BioMarin will conduct preclinical studies of the Fusogenix-formulated candidates to evaluate their potential as therapies to prevent or treat these conditions.


pH Partners, LLC served as financial advisor to Entos.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and preclinical product candidates. For additional information, please visit Information on such website is not incorporated by reference into this press release.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

 About Entos Pharmaceuticals, Inc.

Entos develops next generation nucleic acid-based therapies using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix is formulated with FAST proteins to deliver mRNA or DNA directly into the cytosol of target cells for translation into protective and therapeutic vaccines and medicines. For more information, visit


Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.